Epstein-Barr virus-associated B cell lymphoproliferative disorder following mismatched related T cell-depleted bone marrow transplantation

Bone Marrow Transplantation

Volumn 28, Issue 12, 2001, Pages 1117-1123

  Chiang, K Y ^a   Hazlett, L J ^b   Godder, K T ^c   Abhyankar, S H ^d   Christiansen, N P ^d   van Rhee, F ^e   Lee, C G ^f   Bridges, K ^f,g   Parrish, R S ^e   Henslee Downey, P J ^h  

^a CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^b Vista Psychiatric Consultants LLC   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d University of Arkansas for Medical Sciences ^*  (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f ST LUKE S HOSPITAL   (United States)

^g Indiana Blood and Marrow Transplantation   (United States)

^h UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

EBV lymphoma; GVHD; Mismatched transplantation; T cell depletion

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; HLA ANTIGEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; RITUXIMAB; STEROID; THIOTEPA; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CHILD; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE COURSE; DONOR; DRUG MEGADOSE; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; INCIDENCE; LEUKOCYTE TRANSFUSION; LYMPHOCYTE DEPLETION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK FACTOR; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; B-LYMPHOCYTES; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HUMANS; INFANT; LYMPHOCYTE DEPLETION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 0035691985     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703311     Document Type: Article

References (26)

1. Bone marrow transplantation in pediatric oncology
2. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus
3. Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders
4. Risk factors and pathogenesis of posttransplant lymphoproliferative disorders
5. Epstein-Barr virus-associated lymphoproliferative disorder following autologous bone marrow transplantation for non-Hodgkin's lymphoma
6. Polyclonal Epstein-Barr virus-associated lymphoproliferative disorder following autografting for chronic myeloid leukemia
7. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation
8. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: Risk factors, treatment and outcome
9. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children
10. Epstein-Barr virus lymphoproliferation after bone marrow transplantation
11. Malignant neoplasms following bone marrow transplantation
12. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study
13. Use of partially mismatched related donors extends access to all allogeneic marrow transplant
14. Comparison of engraftment and acute GvHD following transplantation of partially mismatched grafts T cell depleted with OKT3 or T10B9 monoclonal antibody
15. Low incidence of Epstein-Barr virus associated B cell lymphoproliferative disorders following partially mismatched related donor bone marrow transplant
16. Late onset Epstein-Barr virus-associated lymphoproliferative disease after allogeneic bone marrow transplant presenting as breast masses
17. Nonparametric estimation from incomplete observation
18. Risk of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants
19. Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non-identical T-depleted bone marrow transplantation
20. Systemic lymphoblastic response to antithymocyte globulin in renal allograft recipients: An initial report
21. Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin
22. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease
23. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation
24. Human immunoglobulin preparations suppress the occurrence of Epstein-Barr virus-associated lymphoproliferation
25. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome
26. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation